2026 First Extraordinary General Meeting Resolution Announcement

Wuhan Easy Diagnosis Biomedicine Co., Ltd.·August 13, 2026·9 pages

✨ AI Summary

Wuhan Mindray Bio-Medical Electronics Co., Ltd. held its first extraordinary general meeting on August 13, 2026. The meeting approved proposals related to the company's restructuring, including the overall plan, the target asset, transaction counterparty, transaction price, capital source, and payment arrangements. All proposals passed with high approval rates, including from minority shareholders.

Summary generated by AI · Always verify with source document

Exchange Summary

EGM RESOLUTION

The Company held its 1st Extraordinary General Meeting of 2026 on 13 August 2026, during which the following proposal(s) was/were approved: 1. The transaction is in compliance with relevant laws and regulations 2. Transaction plan 2.1. Overall plan of the transaction 2.2. Underlying assets 2.3. Transaction counterparties 2.4. Transaction consideration 2.5. Source of funds for the transaction 2.6. Arrangement for payment of the transaction consideration 2.7. Arrangement for the profits and losses during the transitional period 2.8. Arrangement for the accumulated retained profits 2.9. Performance commitments, and reward and compensation arrangement 2.10. Contractual obligations and liabilities for breach of contract of handling the transfer of the ownership of relevant assets 2.11. Valid period of the resolution 3. The transaction does not constitute a connected transaction 4. The transaction constitutes a major assets restructuring 5. Relevant agreements on the transaction to be signed 6. The Company's share price fluctuation before the first release of the restructuring plan 7. The transaction is in compliance with Article 11 and not applicable to Articles 43 and 44 of the Management Measures on Major Assets Restructuring of Listed Companies 8. The transaction is in compliance with Article 4 of Listed Companies Regulation Guidance No. 9 - Regulatory Requirements for Planning and Implementing Major Assets Restructuring of Listed Companies 9. The transaction does not constitute a listing by restructuring as defined by Article 13 in the Management Measures on Major Assets Restructuring of Listed Companies 10. The circumstances as provided for by Article 12 of the Listed Companies Regulation Guidelines No. 7 - Regulation of Abnormal Stock Trading in Listed Companies Related to Major Assets Restructuring do not apply to the transaction parties 11. Diluted immediate return after the transaction, filling measures, and relevant commitments 12. Audit report, pro forma review report and asset evaluation report related to the transaction 13. Independence of the evaluation institution, rationality of the evaluation hypothesis, correlation between the evaluation method and evaluation purpose, and fairness of the evaluated price 14. Pricing basis of the transaction and the rationality 15. Completeness and compliance of the legal procedure of the transaction and effectiveness of the legal documents submitted 16. Confidentiality measures and system adopted for the transaction 17. Statement on assets purchase and sale within 12 months prior to the transaction 18. Full authorization to the board to handle matters regarding the transaction 19. Statement on whether there is a direct or indirect paid employment of other third-party institutions or individuals for the transaction 20. Expansion of the Company's business scope and amendments to the Company's articles of association 21. Audit report with an extended period and pro forma audit report related to the transaction 22. Report (revised draft) on major assets purchase and its summary 23. Termination of some projects financed with raised funds and change of the purpose of some raised funds

Provided by Shenzhen Stock Exchange

Full Translation

AI Translation· gemini_document

Securities Code: 002932

Securities Abbreviation: *ST Mingde

Announcement No.: 2026-061

Wuhan Mindray Bio-Medical Electronics Co., Ltd.

2026 First Extraordinary General Meeting Resolution Announcement

The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and contains no false records, misleading statements, or significant omissions.

Special Notes:

No proposals were rejected at this general meeting.
This general meeting did not alter resolutions previously passed by shareholders.
This general meeting approved the proposal to amend the company's articles of association.
This general meeting approved the proposal regarding the restructuring matter.

I. Meeting Convening and Attendance

(I) Meeting Convening

The on-site meeting commenced at 14:00 on August 13, 2026 (Thursday).
Online voting period: The specific times for online voting through the Shenzhen Stock Exchange trading system were: August 13, 2026, from 9:15-9:25, 9:30-11:30, and 13:00-15:00. The specific times for voting through the Shenzhen Stock Exchange internet voting system were: any time from 9:15 to 15:00 on August 13, 2026.
Meeting method: This general meeting was held through a combination of on-site voting and online voting.
Meeting convener: The Board of Directors.
Meeting chairperson: Ms. Chen Lili, Chairperson of the Board.
The convening and holding of the meeting complied with the "Company Law of the People's Republic of China," the "Shenzhen Stock Exchange Stock Listing Rules," the "Shenzhen Stock Exchange Listed Company Self-Regulatory Guidelines No. 1 - Standardized Operation of Main Board Listed Companies," and other relevant laws, administrative regulations, departmental rules, normative documents, and the "Articles of Association."

(II) Attendance

Overall attendance of shareholders:

A total of 177 shareholders (including shareholder proxies) attended the meeting through on-site and online voting, representing 108,855,736 shares, or 51.8239% of the company's total voting shares.

Of these, 17 shareholders attended via on-site voting, representing 104,752,554 shares, or 49.8705% of the company's total voting shares.

160 shareholders attended via online voting, representing 4,103,182 shares, or 1.9534% of the company's total voting shares.

Overall attendance of minority shareholders:

A total of 174 minority shareholders attended the meeting through on-site and online voting, representing 6,993,790 shares, or 3.3296% of the company's total voting shares.

Of these, 14 minority shareholders attended via on-site voting, representing 2,890,608 shares, or 1.3762% of the company's total voting shares.

160 minority shareholders attended via online voting, representing 4,103,182 shares, or 1.9534% of the company's total voting shares.

All directors and senior management personnel of the company attended or were present at the general meeting. Lawyers from Grandall (Wuhan) Law Firm witnessed the meeting.

II. Proposal Review and Voting Results

This general meeting voted on the proposals through a combination of on-site and online voting. The voting results are as follows:

Proposal Code	Proposal Name	Voting Category	Number of Votes (Shares)	Percentage	Number of Votes (Shares)	Percentage	Number of Votes (Shares)	Percentage	Voting Result
1.00	Proposal on whether the current transaction complies with relevant laws and regulations	Total Voting Rights	108,815,771	99.963%	36,884	0.033%	3,081	0.0028%	Passed
		Of which, minority shareholders' voting rights	6,953,825	99.428%	36,884	0.527%	3,081	0.0441%
2.00	Proposal on the transaction plan

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.